Monday, 4 January 2016

More remyelination cues found

Syed YA, Zhao C, Mahad D, Möbius W, Altmann F, Foss F, Sentürk A, Acker-Palmer A, Lubec G, Lilley K, Franklin RJ, Nave KA, Kotter MR. Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination. Acta Neuropathol. 2015 Dec. [Epub ahead of print]

Remyelination in multiple sclerosis (MS) lesions often remains incomplete despite the presence of oligodendrocyte progenitor cells (OPCs). Amongst other factors, successful remyelination depends on the phagocytic clearance of myelin debris. However, the proteins in myelin debris that act as potent and selective inhibitors on OPC differentiation and inhibit CNS remyelination remain unknown. Here, we identify the transmembrane signalling protein 
Syed YA, Zhao C, Mahad D, Möbius W, Altmann F, Foss F, Sentürk A, Acker-Palmer A, Lubec G, Lilley K, Franklin RJ, Nave KA, Kotter MR. as important mediator of this inhibition, using a protein analytical approach in combination with a primary rodent OPC assay. In the presence of EphrinB3, OPCs fail to differentiate. In a rat model of remyelination, infusion of EphrinB3 inhibits remyelination. In contrast, masking EphrinB3 epitopes using antibodies promotes remyelination. Finally, we identify EphrinB3 in MS lesions and demonstrate that MS lesion extracts inhibit OPC differentiation while antibody-mediated masking of EphrinB3 epitopes promotes it. Our findings suggest that EphrinB3 could be a target for therapies aiming at promoting remyelination in demyelinating disease.

EFNB3, a member of the ephrin gene family, is important in brain development as well as in its maintenance. The EPH and EPH-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases. EPH receptors typically have a single kinase domain and an extracellular region containing a Cysteine-rich domain and 2 fibronectin type III repeats. The ephrin ligands and receptors have been named by the Eph Nomenclature Committee (1997) based on their structures and sequence relationships. Ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. Ephrin-B ligands also contain an intracellular tail with highly conserved tyrosine residues and a PDZ-binding motif at the C-terminus. This tail functions as a mechanism for reverse signaling, where signaling occurs into the ligand-containing cell, as opposed to the cell with the receptor. Upon receptor-ligand interaction the tyrosine residues become phosphorylated and there is recruitment of PDZ domain-containing proteins.The Eph family of receptors are similarly divided into two groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands.EphrinB3 has been implicated in mediating various developmental events, particularly in the nervous system. EphrinB3 reverse signaling is important for axon pruning and synapse and spine formation during postnatal development of the nervous system. Previous work has also shown that signaling through this ligand is important for radial migration during cortical development. Moreover, levels of EFNB3 expression are particularly high in several forebrain subregions compared to other brain subregions, and may play a pivotal role in forebrain function. It has been suggested that ephrinB3 signaling is necessary for synaptic plasticity to occur in the hippocampus; this implicates ephrinB3 as a major player in learning and memory. More recently, ephrinB3 has been shown to regulate proliferation of neural stem cells in the adult subventricular zone (SVZ)

So more molecules to control remyelination but will an antibody be any good for this purpose? First it has to get into the brain then it has to get inside the cell, which is not easy. Again as with  many of these molecules they are signalling molecules that are used for other purposes. So can they be used long term, but the firstquestion is do they need to be, or will a short course of treatment do the trick.


  1. How can people re-discover what is already known!!! Ephrin is well characterized.

  2. So it is known that ephrin is involved in remyelination - do you think that there could be a way to encourage this process to happen Doc G? (Just asking - perhaps the whole thing begs too many questions)

    1. What the authors do not mention is that most of these molecules have soluble factors and are probably acting in autocrine and paracrine fashion to encourage growth.


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.